Fiche publication
Date publication
janvier 2021
Journal
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Auteurs
Membres identifiés du Cancéropôle Est :
Pr HUMBERT Philippe
,
Mr LIHOREAU Thomas
Tous les auteurs :
Marty P, Chatelain B, Lihoreau T, Tissot M, Dirand Z, Humbert P, Senez C, Secomandi E, Isidoro C, Rolin G
Lien Pubmed
Résumé
Keloids are characterized by increased deposition of fibrous tissue in the skin and subcutaneous tissue following an abnormal wound healing process. Although keloid etiology is yet to be fully understood, fibroblasts are known to be key players in its development. Here we analyze the antifibrotic mechanisms of Halofuginone (HF), a drug reportedly able to inhibit the TGF-β1-Smad3 pathway and to attenuate collagen synthesis, in an in-vitro keloid model using patient-derived Keloid Fibroblasts (KFs) isolated from fibrotic tissue collected during the "Scar Wars" clinical study (NCT NCT03312166). TGF-β1 was used as a pro-fibrotic agent to stimulate fibroblasts response under HF treatment. The fibrotic related properties of KFs, including survival, migration, proliferation, myofibroblasts conversion, ECM synthesis and remodeling, were investigated in 2D and 3D cultures. HF at 50 nM concentration impaired KFs proliferation, and decreased TGF-β1-induced expression of α-SMA and type I procollagen production. HF treatment also reduced KFs migration, prevented matrix contraction and increased the metallo-proteases/inhibitors (MMP/TIMP) ratio. Overall, HF elicits an anti-fibrotic contrasting the TGF-β1 stimulation of KFs, thus supporting its therapeutic use for keloid prevention and management.
Mots clés
Fibrosis, Halofuginone, Keloid, Myofibroblasts, TGF-β1
Référence
Biomed Pharmacother. 2021 Jan 8;135:111182
